ATE537187T1 - Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung - Google Patents

Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung

Info

Publication number
ATE537187T1
ATE537187T1 AT05757060T AT05757060T ATE537187T1 AT E537187 T1 ATE537187 T1 AT E537187T1 AT 05757060 T AT05757060 T AT 05757060T AT 05757060 T AT05757060 T AT 05757060T AT E537187 T1 ATE537187 T1 AT E537187T1
Authority
AT
Austria
Prior art keywords
class
antigen
production
composition containing
vaccine composition
Prior art date
Application number
AT05757060T
Other languages
English (en)
Inventor
Frederic Triebel
Original Assignee
Immutep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep filed Critical Immutep
Application granted granted Critical
Publication of ATE537187T1 publication Critical patent/ATE537187T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT05757060T 2004-04-13 2005-04-13 Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung ATE537187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403848A FR2868781B1 (fr) 2004-04-13 2004-04-13 Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
PCT/FR2005/000894 WO2005103079A1 (fr) 2004-04-13 2005-04-13 Composition de vaccin comprenant un ligan cmh de classe ii couple a un antigene, procede de preparation et utilisations

Publications (1)

Publication Number Publication Date
ATE537187T1 true ATE537187T1 (de) 2011-12-15

Family

ID=34944934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05757060T ATE537187T1 (de) 2004-04-13 2005-04-13 Impfstoffzusammensetzung enthaltend einen klasse- ii-mhc-liganden gekoppelt mit einem antigen, verfahren zu dessen herstellung und dessen verwendung

Country Status (8)

Country Link
US (1) US20080003235A1 (de)
EP (1) EP1735344B1 (de)
JP (1) JP5000481B2 (de)
CN (1) CN101010341A (de)
AT (1) ATE537187T1 (de)
CA (1) CA2560891C (de)
FR (1) FR2868781B1 (de)
WO (1) WO2005103079A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902101B1 (fr) * 2006-06-12 2012-12-28 Scras Peptides a activite anti-proliferative
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
TW201725050A (zh) * 2015-10-09 2017-07-16 創祐生技股份有限公司 臺北市南港區園區街3號17樓 Wr-09 抗癌疫苗組合
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
US20240247043A1 (en) * 2021-05-08 2024-07-25 Wuhan Yzy Biopharma Co., Ltd. Lag-3 protein mutant, and preparation and use thereof
WO2025242209A1 (zh) * 2024-05-24 2025-11-27 杭州阿诺生物医药科技有限公司 一种融合多肽及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0758383T3 (da) * 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US6482925B1 (en) * 1996-11-28 2002-11-19 Applied Research Systems Ars Holding N.V. Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
ATE231917T1 (de) * 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine

Also Published As

Publication number Publication date
CN101010341A (zh) 2007-08-01
JP2008501635A (ja) 2008-01-24
EP1735344A1 (de) 2006-12-27
JP5000481B2 (ja) 2012-08-15
US20080003235A1 (en) 2008-01-03
CA2560891A1 (fr) 2005-11-03
WO2005103079A1 (fr) 2005-11-03
CA2560891C (fr) 2013-08-20
FR2868781A1 (fr) 2005-10-14
FR2868781B1 (fr) 2008-02-22
EP1735344B1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE381564T1 (de) Arylsubstituierte polycyclische amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE497984T1 (de) Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung
ATE521708T1 (de) Chimärische, hybrid- und tandem-polypeptide von meningococcus nmb1870
ATE490256T1 (de) Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE382049T1 (de) Neue 2-benzylaminodihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
CY1108306T1 (el) Αναστολεις αζαϊνδολιου των mtp και apob
ATE488623T1 (de) Polymere strukturen und verfahren zu deren herstellung
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
MX342788B (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos.
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
DE602004012796D1 (de) Dichtungsprofil, Verfahren zu seiner Herstellung und Formwerkzeug zur Verwendung in diesem Verfahren
DE502006005581D1 (de) Ukmischungen, ein verfahren zu deren herstellung, verfahren zur herstellung von verbund-formteilen und deren verwendung
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
DE502004012162D1 (de) Elektrosterisch stabilisierte wässrige polyurethan-harze, verfahren zu ihrer herstellung und deren verwendung
ATE496041T1 (de) 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
ATE372336T1 (de) Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
DE602006010934D1 (de) Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
DE602004026157D1 (de) Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
FR2868781B1 (fr) Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
DE502006006943D1 (de) Formaldehydarmes lignocellulosematerial und verfahren zu dessen herstellung
ATE380191T1 (de) Gemischtes olanzapinsolvat, verfahren zu dessen herstellung und verfahren zur herstellung von olanzapin-form i daraus
ATE487706T1 (de) Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel